- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To explore the pharmakokinetic/pharmacodynamic relationships at different doses of degarelix in benign prostatic hyperplasia (BPH) patients and to select doses and dosing regime for Phase II efficacy trials.
Critère d'inclusion
- Patients with Benign Prostata Hypertropia (BPH) who fulfil the following criteria: a prostate volume of more than 30 mL, maximal uroflow of 12 mL/s or less; International Prostate Symptom Score (IPSS) of 13 or more, a serum prostate specific antigen (PSA) value below 10 ng/mL and no evidence of prostate cancer will be included in the study